Bluelight.org

Welcome from Rick Doblin and MAPS

  • 384
  • 31
Dear Bluelight & MAPS community,

As the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS), I'm honored and excited to welcome you to the MAPS Forums on Bluelight. MAPS and Bluelight have grown together over the years and have been mutually supportive, with this new partnership signifying a new depth in our work together.

MAPS' work has two main goals, which go hand in hand: discovering ways to use psychedelics and marijuana safely and beneficially, and educating people about how to reduce the harms associated with their use. Open, scientifically-informed conversations about the risks and benefits of psychedelics and marijuana pushes back the stigma that has built up around them, and allows us to create new, more just policies and a safer, more open cultural attitude to psychedelics, marijuana, and human consciousness in general.
Continue…

Do Antidepressants Impair the Ability to Extinguish Fear?

  • 435
  • 61
This is why I say it is wrong to use antidepressants as anti-anxiety drugs...

Using it to cover up the depression in a toxic way creates more harm than good...
Continue…

Introducing Bluelight's Donations Portal!

  • 150
  • 1
Attention Bluelighters!

I want to thank all of you for your patience while we’ve been gearing up for Bluelight's first ever donations campaign. I know I speak for The_Love_Bandit and the Admin team when I say we wanted to create a solution that offered the most to our members.

Long ago, we could have created a simple "click and donate" function, but it was our desire to allow all Bluelight donations to be 501(c)(3) tax deductible. Perhaps not many members will claim their donations on their taxes, but we believe it says something about the caliber of Bluelight as a community.

It is with great enthusiasm and pride that I announce we have reached such an arrangement with our friends at MAPS.org, who have graciously agreed to facilitate Bluelight’s donations under their 501(c)(3) umbrella. On behalf of all of us on Bluelight staff, I am happy to announce the launch of the Bluelight Donations Portal.
Continue…

The war on drugs is about the disposal of excess Americans; "a holocaust in slow motion" says Wire creator David Simon

  • 360
  • 42
I agree, put this on the first page! Good read.
Continue…

Pledge to the Community

  • 412
  • 31
Dear Bluelight & MAPS community,

As the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS), I'm honored and excited to welcome you to the MAPS Forums on Bluelight. MAPS and Bluelight have grown together over the years and have been mutually supportive, with this new partnership signifying a new depth in our work together.

MAPS' work has two main goals, which go hand in hand: discovering ways to use psychedelics and marijuana safely and beneficially, and educating people about how to reduce the harms associated with their use. Open, scientifically-informed conversations about the risks and benefits of psychedelics and marijuana pushes back the stigma that has built up around them, and allows us to create new, more just policies and a safer, more open cultural attitude to psychedelics, marijuana, and human consciousness in general.
Continue…

Research Standards

  • 426
  • 61
Science Daily

June 10, 2013 — An interesting new report of animal research published in Biological Psychiatry suggests that common antidepressant medications may impair a form of learning that is important clinically.

Selective serotonin reuptake inhibitors, commonly called SSRIs, are a class of antidepressant widely used to treat depression, as well as a range of anxiety disorders, but the effects of these drugs on learning and memory are poorly understood.

In a previous study, Nesha Burghardt, then a graduate student at New York University, and her colleagues demonstrated that long-term SSRI treatment impairs fear conditioning in rats. As a follow-up, they have now tested the effects of antidepressant treatment on extinction learning in rats using auditory fear conditioning, a model of fear learning that involves the amygdala. The amygdala is a region of the brain vitally important for processing memory and emotion.

They found that long-term, but not short-term, SSRI treatment impairs extinction learning, which is the ability to learn that a conditioned stimulus no longer predicts an aversive event.
Continue…

Neurons to Nirvana: Understanding Psychedelic Medicines

  • 162
  • 0
Last year, we asked Bluelighters to help in fund an amazing project from Oliver Hockenhull - the film Neurons to Nirvana. Unfortunately, despite achieving their 'kickstarter' targets, funding fell through. Regardless of this setback, the team at Mangusta Productions have managed to get the film to the release stage! But they still need a small fund to create a marketing and distribution plan, and allow them to spread the truth about psychedelics globally.
Continue…

Why Do We Treat Heroin Addicts Like They Deserve to Die?

  • 536
  • 220
yeah very good article basically sums up why some humans are such pieces of shit to others. What's there to do about this though when it is intentionally set up this way by others? The drug trade, Law enforcement, big pharma, prison industry, government all have a hand in the same setup (The drug war), along with greed and capitalism, these people have tremendous power, global influence and i imagine will not be easily swayed by appeals to humanity. I'm sure some people in earnest believe in the drug war but i bet the large majority know why we keep this charade up. If those people in power have to identify with heroin addicts as human beings equal to themselves then there's no way they could keep this drug war up, of course they don't give a fuck in the first place which is the real problem IMO.

it's not going to be like Germany's destruction, this drug war can play out forever unless enough actual people put a stop to it as in some sort of revolution.
Continue…

Open Your Mind to the New Psychedelic Science

  • 295
  • 27
Fringe or frontier?

As many are aware, a good crop of psychedelic therapy studies are underway...if Phase I/II trials look good in terms of safety and efficacy, one can hope that NIH/NIMH will come around to the idea of funding some of these studies in the not-too-distant future.

Here's a more complete list of recent/ongoing studies:

Ayahuasca
- Depression: Brazil (upcoming)
Psilocybin
- End-of-life anxiety: UCLA (completed), NYU (ongoing), Hopkins (ongoing)
- Smoking cessation: Johns Hopkins (ongoing)
- Alcoholism: U of NM (ongoing), NYU (pending)
- Enhancing meditation/spiritual practice: Hopkins (ongoing)
- Depression: UK (pending)
MDMA
- PTSD: Switzerland (completed), Spain (completed), Israel (ongoing), University of Colorado (ongoing), South Carolina (completed and ongoing), Canada (pending)
LSD
- End-of-life anxiety: Switzerland (completed)
Ibogaine
- Addiction: Mexico, New Zealand (ongoing)
Continue…

The real driver behind most drug use is pleasure, not dependence

  • 322
  • 37
Surprisingly good article, thanks for posting.
Continue…
Top